Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin.
Cysteinyl leukotrienes (CysLTs) play an important role in eosinophilic airway inflammation. In addition to their direct chemotactic effects on eosinophils, indirect effects have been reported. Eotaxin is a potent eosinophil-specific chemotactic factor produced mainly by fibroblasts. We investigated whether CysLTs augment eosinophilic inflammation via eotaxin production by fibroblasts. Leukotriene (LT)C(4) alone had no effect on eotaxin production by human fetal lung fibroblasts (HFL-1). However, LTC(4) stimulated eotaxin production by IL-13-treated fibroblasts, thereby indirectly inducing eosinophil sequestration. Unstimulated fibroblasts did not respond to LTC(4), but coincubation or preincubation of fibroblasts with IL-13 altered the response to LTC(4). To examine the mechanism(s) involved, the expression of CysLT1R in HFL-1 was investigated by quantitative real-time PCR and flow cytometry. Only low levels of CysLT1R mRNA and no CysLT1R protein were expressed in unstimulated HFL-1. In contrast, stimulation with IL-13 at a concentration of 10 ng/ml for 24 h significantly up-regulated both CysLT1R mRNA and protein expression in HFL-1. The synergistic effect of LTC(4) and IL-13 on eotaxin production was abolished by CysLT1R antagonists pranlukast and montelukast. These findings suggest that IL-13 up-regulates CysLT1R expression, which may contribute to the synergistic effect of LTC(4) and IL-13 on eotaxin production by lung fibroblasts. In the Th2 cytokine-rich milieu, such as that in bronchial asthma, CysLT1R expression on fibroblasts might be up-regulated, thereby allowing CysLTs to act effectively and increase eosinophilic inflammation.
Chibana
Kazuyuki
K
Department of Pulmonary Medicine and Clinical Immunology, Dokkyo University School of Medicine, Tochigi, Japan.
Ishii
Yoshiki
Y
Asakura
Takuma
T
Fukuda
Takeshi
T
D002460:Cell Line; D002474:Cell-Free System / Q000276:immunology / Q000378:metabolism; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000032:analysis / Q000096:biosynthesis*; D002631:Chemotactic Factors, Eosinophil / Q000032:analysis / Q000096:biosynthesis; D004357:Drug Synergism; D005333:Fetus; D005347:Fibroblasts / Q000276:immunology* / Q000378:metabolism; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000276:immunology; D006801:Humans; D018793:Interleukin-13 / Q000502:physiology*; D017997:Leukotriene C4 / Q000502:physiology*; D017998:Leukotriene D4 / Q000378:metabolism*; D008168:Lung / Q000166:cytology / Q000196:embryology / Q000276:immunology* / Q000378:metabolism; D008565:Membrane Proteins; D012333:RNA, Messenger / Q000096:biosynthesis; D018077:Receptors, Leukotriene / Q000096:biosynthesis* / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015854:Up-Regulation / Q000235:genetics / Q000276:immunology*
C515456:CCL11 protein, human; D054413:Chemokine CCL11; D019742:Chemokines, CC; D002631:Chemotactic Factors, Eosinophil; D018793:Interleukin-13; D008565:Membrane Proteins; D012333:RNA, Messenger; D018077:Receptors, Leukotriene; D017997:Leukotriene C4; D017998:Leukotriene D4; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor